Various drugs
- PDF / 170,198 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 90 Downloads / 160 Views
1 S
Various side effects: 6 case reports In a retrospectively study between July 2014 and July 2018, 6 patients including a 2 women aged 68–71 years and 2 men aged 56–58 years [not all ages and sexes stated] were described, who developed pneumonitis, pancolitis, enteritis, segmental colitis associated with diverticulosis or thyroiditis during treatment with pembrolizumab, atezolizumab, nivolumab or ipilimumab [dosages, routes, durations of treatments to reaction onsets and outcome not stated] The patients had small-cell lung cancer. Of the 6 patients, 2 patients developed pneumonitis due to pembrolizumab and atezolizumab each. Of the two women; the 68-year-old woman was receiving monotherapy with nivolumab. After 2.6 weeks from treatment initiation, her CT scan showed diffuse wall thickening and mucosal hyperemia of the entire colon that suggested pancolitis and thickening and mucosal hyperemia were also noted in the small bowel loops suggesting enteritis. The 71-year-old woman, received treatment with nivolumab and ipilimumab. After 5 weeks from treatment initiation, CT scan showed new enlargement and heterogeneous enhancement of the thyroid gland that suggested thyroiditis. Also laboratory investigation showed elevated TSH. Of the two men; the 56-year-old man was receiving treatment with nivolumab and ipilimumab. After 1.4 weeks from treatment initiation, CT scan showed diffuse ground glass and reticular opacities throughout both lungs, with areas of consolidation, representing pneumonitis with an acute interstitial pneumonia/acute respiratory distress syndrome pattern. The 58-year-old man received treatment with nivolumab and ipilimumab. After 17.9 weeks from treatment initiation, CT scan showed diffuse wall thickening and mucosal hyperemia of the sigmoid colon with mesenteric vessel engorgement that suggested colitis with a segmental colitis associated with diverticulosis (SCAD). The man was asymptomatic and was treated conservatively, and his followup CT showed resolution of the findings of SCAD in the sigmoid colon. Park H, et al. Immune-related adverse events on body CT in patients with small-cell lung cancer treated with immune-checkpoint inhibitors. European Journal of Radiology 803518382 132: Nov 2020. Available from: URL: http://doi.org/10.1016/j.ejrad.2020.109275
0114-9954/20/1833-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 5 Dec 2020 No. 1833
Data Loading...
